The activation of NMDA receptors that subsequently induce cell death is believed to be primarily caused by an influx of Ca
2+ into the cells, which leads to the generation of free radicals.
29 In addition, it has also been reported that an enhancement of the reactive oxygen species (ROS) production occurs after excessive increases in the intracellular free Ca
2+ concentration.
8 The predominant form of glutamate neurotoxicity that occurs in retinal tissues has been shown to be mediated by an overstimulation of the NMDA subtype of glutamate receptors. As a result, this causes an increase of the Ca
2+ influx, which is then followed by cell death.
6,30,31 Furthermore, in various eye diseases, such as retinal ischemia, glaucoma, diabetic retinopathy, and age-related macular degeneration, it has been proposed that glutamate excitotoxicity and oxidative stress contribute to the retinal damage that occurs in these disorders.
32–34 An increase in the retinal angiotensinogen mRNA has also been found after ischemic injury to the retina of rats.
22 We previously examined ischemia-reperfusion in rats and found that there were increases in the AT1-R expression starting at 3 hours, with the peak expression occurring at 12 hours after the ischemia-reperfusion.
18 In a subsequent study, we found the ROS production that occurred after a 12-hour ischemia-reperfusion was mediated by a nicotinamide adenine dinucleotide phosphate oxidative pathway.
20 Overall, these results indicate that the ROS production that causes the retinal injury occurs via the local RAAS. Thus, these findings demonstrate that not only the NMDA receptor–mediated signal but also the RAAS are important pathways that are involved in retinal neuronal degeneration. Our current study showed that while spironolactone protected against RGC death after the local administration of aldosterone, memantine did not. In contrast, our study also found that memantine but not spironolactone protected against RGC death after local administration of NMDA. Thus, these results indirectly show that RAAS does not exist downstream of the NMDA receptor–mediated signal and that the NMDA receptor–mediated signal does not exist downstream of the RAAS.